Fixed dose ophthalmic pharmaceuticals made up of brinzolamide (BRZ) and timolol maleate (TML) must be characterized through an analysis which enables quantitative determination of both substances in a single mixture without depending on the use of solvent for routine product quality control. In this case, the present paper will assess if the first order derivative UV-spectrophotometric method could provide adequate basis for making decisions concerning the quality control of BRZ-TML products taking into consideration their calibration margin, recovery, balance of formulation, and environmental cost. Analytical data included derivative wavelengths 248.80 nm and 297.60 nm for BRZ and TML respectively; calibration interval range 4-24 and 5-25 μg mL-1; detection and quantification limits; 6 triplicate recovery series; assay values of three commercially available formulations and one in situ gel; as well as greenness values from AGREE, eco-scale, and penalty point calculations. Linearity coefficients of R2=0.9998 and R2=0.9999 were determined in the case of BRZ and TML respectively. Quantification limits of 0.91 μg mL-1 (BRZ) and 2.99 μg mL-1 (TML) were found, corresponding to a sensitivity ratio of 4.40 and 1.67 against the first calibration point. Recoveries varied between 97.43-103.22% (BRZ) and 101.73-103.34% (TML), where all relative standard deviations were under 2%. Assay values of the test products ranged between 102.63-105.39% for BRZ and 102.52-105.68% for TML. An in situ gel preparation gave the most balanced paired assay with only 0.03 percentage point difference between BRZ and TML. The derivative UV method further yielded AGREE score 0.77, eco-scale score 88, and 12 penalty points reflecting its low environmental impact as compared to its competitor, the chromatographic method.